TRI-611

PreclinicalSmall molecule

TTRIANA Biomedicines, Inc.

TRI-611 is one of 4 small molecule programs targeting ALK Positive. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ALK PositiveRecruiting

ALK PositivePreclinical

Recruiting

Competition

Competitive Landscape

3 competitors in ALK Positive

#DrugCompanyPhaseTrials

Alecensa

Roche

Phase 3

2 2

Lorbrena

Pfizer

Phase 2

2 3

NXP900

NNuvectis Pharma, Inc.

Phase 1

1 4

TRI-611

TTRIANA Biomedicines, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2034

PreclinicalRecruiting

ALK Positive

NCT07491497

Clinical

Trials by Indication[1]

ALK Positive1 trial

A Phase 1/2, Dose Escalation and Expansion Study of TRI-611, an Oral ALK Molecular Glue Degrader in Participants With Advanced ALK-Positive NSCLC

Recruiting·TTRIANA Biomedicines, Inc.·Preclinical·NCT07491497·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TRI-611. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TRI-611 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TRI-611. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — TRIANA Biomedicines, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TTRIANA Biomedicines, Inc.

TRI-611

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2034

Trials by Indication[1]

ALK Positive1 trial

References

Drug Info

Quick Facts

Related News